Skip to main content

Resources and support for patients prescribed TYMLOS.

TYMLOS patient support—there when you and your patients need it.

Jump to section Arrow Icon
Prescribing Resources and DownloadsSavings Card ProgramSpecialty Pharmacy Information
TYMLOS CoverageVirtual Injection TrainingPatient Downloads

Prescribing resources and downloads.

Patient Enrollment Form

Send your prescription to the Support Center by:

E-prescribing TYMLOS through your EHR system to "Careform Pharmacy" (NPI:1043762750).

Be sure to include the ICD-10 diagnosis code with your e-prescription.

Or

Downloading an enrollment form below, ensuring your patient has signed it, then faxing the completed form, along with a copy of the insurance card (medical and pharmacy), to the Support Center at 1‑800‑910‑4610.

Download (opens in a new tab)
Example of TYMLOS specialty pharmacy intake form

TYMLOS Specialty Pharmacy Intake Form

Complete this form and fax it directly to a specialty pharmacy that dispenses TYMLOS.

Download (opens in a new tab)
Example of sample of prior authorization (PA) cover letter

Sample of Prior Authorization (PA) Cover Letter

Some health plans require a PA request form in order to satisfy their policy requirements to obtain TYMLOS coverage. Use this sample letter as a template to help you get started.

Download (opens in a new tab)
Example of sample letter of appeal.

Sample Letter of Appeal

If a health plan denies TYMLOS coverage, they may require a letter of appeal along with a letter of medical necessity in order to reconsider the decision. This template can help you write your own letter of appeal.

Download (opens in a new tab)
Example of sample letter of medical necessity.

Sample Letter of Medical Necessity

Some health plans require a letter of medical necessity in addition to a letter of appeal that may help justify the clinical rationale for covering TYMLOS. Use this template to write a letter of medical necessity.

Download (opens in a new tab)

Access and affordability.

From insurance coverage to potential savings on treatment, the Radius Support team is available to assist you and your patients.

Call Monday through Friday, 8AM to 7PM ET, at
1-866-896-5674navigation arrow

Savings Card

Eligible,* commercially insured patients can pay as little as $0 a month for their TYMLOS prescription. There is an annual cap on the amount of assistance patients can receive over a 1-year period.1

QuantityDownload (opens in a new tab)

* This offer is not valid for patients using Medicare, Medicaid, or other government-funded programs to pay for their medications. See back of Savings Card for all eligibility requirements, rules, and restrictions. Savings Card is available for patients to download at TYMLOS.com. Limited to one offer per person.1

TYMLOS Savings Card for abaloparatide injection, pay as little as $0 per month. See eligibility, rules and restrictions.

Explaining a Specialty Pharmacy to Your Patients

Explaining a Specialty Pharmacy (SP) to Your Patients

Use this guide to help answer questions your patients may have about receiving their prescription from an SP.

TYMLOS Specialty Pharmacy Network List

See a list of non-integrated delivery network SPs that are able to dispense TYMLOS. In addition, SPs affiliated with an integrated delivery network are able to dispense TYMLOS.

Download (opens in a new tab)

Specialty Pharmacy information.

Specialty Pharmacy (SP) information.

Once a prescription has been received, the Support Center will conduct an insurance verification to confirm coverage for TYMLOS, obtain estimated out-of-pocket costs, determine if a prior authorization (PA) is needed, and identify an in-network SP.

Should a PA be required, the SP may reach out to your office for additional information or to submit the PA to the health plan. Prescriptions will be triaged to the patient’s in-network SP whenever possible. The Support Center will provide the pharmacy with the savings card information for eligible patients.

TYMLOS is covered by most commercial and Medicare plans. Individual out-of-pocket costs will vary.1

Section BoxSection Box

Data courtesy of Managed Markets Insight & Technology as of January 1, 2023.

What to do if TYMLOS is not covered under your patient’s insurance plan?

Advise them to call 1-866-896-5674 to learn about Radius Assist, a patient assistance program available to eligible patients who cannot afford their medication.

Radius Patient Access Support Services

The Support Center will provide you with details related to your patients’ insurance benefits, PA requirements, as well as contact information for SPs.

Call1-866-896-5674navigation arrow

Patient resources and downloads.

Encourage your patients to register for virtual injection training.

Injection training is provided through our Clinical Educator Network, which helps patients with a prescription understand how to use the pen and self-inject, and supports them as they start and stay on TYMLOS, as directed by you.

The TYMLOS Clinical Educators are also available to provide training for you and your staff on using the TYMLOS pen.

Encourage your patients to register for virtual training at

www.TYMLOSsignup.com (opens in a new tab)

women-walking-dogwomen-walking-dog
Discover TYMLOS with the patient brochure to share with your patients.

Patient Brochure

This brochure will help your patients understand osteoporosis as a disease, its associated risk factors, and the role TYMLOS plays in treating it. Inside, patients can find information on the TYMLOS patient support program, directions on storage and use, and how to access a savings card.

Download (opens in a new tab)
TYMLOS Prescribing Information.

Prescribing Information

Download the TYMLOS Prescribing Information.

Download (opens in a new tab)
TYMLOS Medication Guide.

Medication Guide.

Download the TYMLOS Medication Guide.

Download (opens in a new tab)
OpenClose

IMPORTANT SAFETY INFORMATION

Contraindications: TYMLOS is contraindicated in patients with a history of systemic hypersensitivity to abaloparatide or to any component of the product formulation. Reactions have included anaphylaxis, dyspnea, and urticaria.

Risk of Osteosarcoma: It is unknown whether TYMLOS will cause osteosarcoma in humans. Osteosarcoma has been reported in patients treated with a PTH-analog in the post marketing setting; however, an increased risk of osteosarcoma has not been observed in observational studies in humans. There are limited data assessing the risk of osteosarcoma beyond 2 years of TYMLOS use. Avoid use of TYMLOS for patients at an increased baseline risk for osteosarcoma including patients with open epiphysis (pediatric and young adult patients); metabolic bone diseases other than osteoporosis, including Paget’s disease of the bone; bone metastases or a history of skeletal malignancies; prior external beam or implant radiation therapy involving the skeleton; or hereditary disorders predisposing to osteosarcoma.

Orthostatic Hypotension: Orthostatic hypotension may occur with TYMLOS, typically within 4 hours of injection. Associated symptoms may include dizziness, palpitations, tachycardia, or nausea, and may resolve by having the patient lie down. For the first several doses, TYMLOS should be administered where the patient can sit or lie down if necessary.

Hypercalcemia: TYMLOS may cause hypercalcemia. TYMLOS is not recommended in patients with pre-existing hypercalcemia or in patients who have an underlying hypercalcemic disorder, such as primary hyperparathyroidism, because of the possibility of exacerbating hypercalcemia.

Hypercalciuria and Urolithiasis: TYMLOS may cause hypercalciuria. It is unknown whether TYMLOS may exacerbate urolithiasis in patients with active or a history of urolithiasis. If active urolithiasis or pre-existing hypercalciuria is suspected, measurement of urinary calcium excretion should be considered.

Pregnancy and Lactation: TYMLOS is not indicated for use in females of reproductive potential.

Adverse Reactions:

  • The most common adverse reactions (incidence ≥2%) reported with TYMLOS in postmenopausal women with osteoporosis are hypercalciuria (11%), dizziness (10%), nausea (8%), headache (8%), palpitations (5%), fatigue (3%), upper abdominal pain (3%), and vertigo (2%).
  • The most common adverse reactions (incidence ≥2%) reported with TYMLOS in men with osteoporosis are injection site erythema (13%), dizziness (9%), arthralgia (7%), injection site swelling (7%), injection site pain (6%), contusion (3%), abdominal distention (3%), diarrhea (3%), nausea (3%), abdominal pain (2%), and bone pain (2%).

INDICATIONS AND USAGE

TYMLOS is indicated for the:

  • treatment of postmenopausal women with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture), or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, TYMLOS reduces the risk of vertebral fractures and nonvertebral fractures.
  • treatment to increase bone density in men with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture), or patients who have failed or are intolerant to other available osteoporosis therapy.
Please see full Prescribing Information. (opens in a new tab)

IMPORTANT SAFETY INFORMATION

Contraindications: TYMLOS is contraindicated in patients with a history of systemic hypersensitivity to abaloparatide or to any component of the product formulation. Reactions have included anaphylaxis, dyspnea, and urticaria.

Risk of Osteosarcoma: It is unknown whether TYMLOS will cause osteosarcoma in humans. Osteosarcoma has been reported in patients treated with a PTH-analog in the post marketing setting; however, an increased risk of osteosarcoma has not been observed in observational studies in humans. There are limited data assessing the risk of osteosarcoma beyond 2 years of TYMLOS use. Avoid use of TYMLOS for patients at an increased baseline risk for osteosarcoma including patients with open epiphysis (pediatric and young adult patients); metabolic bone diseases other than osteoporosis, including Paget’s disease of the bone; bone metastases or a history of skeletal malignancies; prior external beam or implant radiation therapy involving the skeleton; or hereditary disorders predisposing to osteosarcoma.

Orthostatic Hypotension: Orthostatic hypotension may occur with TYMLOS, typically within 4 hours of injection. Associated symptoms may include dizziness, palpitations, tachycardia, or nausea, and may resolve by having the patient lie down. For the first several doses, TYMLOS should be administered where the patient can sit or lie down if necessary.

Hypercalcemia: TYMLOS may cause hypercalcemia. TYMLOS is not recommended in patients with pre-existing hypercalcemia or in patients who have an underlying hypercalcemic disorder, such as primary hyperparathyroidism, because of the possibility of exacerbating hypercalcemia.

Hypercalciuria and Urolithiasis: TYMLOS may cause hypercalciuria. It is unknown whether TYMLOS may exacerbate urolithiasis in patients with active or a history of urolithiasis. If active urolithiasis or pre-existing hypercalciuria is suspected, measurement of urinary calcium excretion should be considered.

Pregnancy and Lactation: TYMLOS is not indicated for use in females of reproductive potential.

Adverse Reactions:

  • The most common adverse reactions (incidence ≥2%) reported with TYMLOS in postmenopausal women with osteoporosis are hypercalciuria (11%), dizziness (10%), nausea (8%), headache (8%), palpitations (5%), fatigue (3%), upper abdominal pain (3%), and vertigo (2%).
  • The most common adverse reactions (incidence ≥2%) reported with TYMLOS in men with osteoporosis are injection site erythema (13%), dizziness (9%), arthralgia (7%), injection site swelling (7%), injection site pain (6%), contusion (3%), abdominal distention (3%), diarrhea (3%), nausea (3%), abdominal pain (2%), and bone pain (2%).

INDICATIONS AND USAGE

TYMLOS is indicated for the:

  • treatment of postmenopausal women with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture), or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, TYMLOS reduces the risk of vertebral fractures and nonvertebral fractures.
  • treatment to increase bone density in men with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture), or patients who have failed or are intolerant to other available osteoporosis therapy.

Please see full Prescribing Information (opens in a new tab).

References: 1. TYMLOS. Prescribing information. Radius Health, Inc. 2. Dempster DW, Zhou H, Rao SD, et al. Early effects of abaloparatide on bone formation and resorption indices in postmenopausal women with osteoporosis. J Bone Miner Res. 2021;36(4):644-653. 3. Baron R, Hesse E. Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives.J Clin Endocrinol Metab. 2012;97(2):311-325. 4. Eriksen EF. Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord. 2010;11(4):219-227. 5. Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316(7):722-733. Published correction appears in JAMA. 2017;317(4):442. 6. Tay D, Cremers S, Bilezikian JP. Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism—translating the pharmacology. Br J Clin Pharmacol. 2018;84(2):252-267. 7. Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ. Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling. Endocrinology. 2016;157(1):141-149. 8. Siddiqui JA, Partridge NC. Physiological bone remodeling: systemic regulation and growth factor involvement. Physiology (Bethesda). 2016;31(3):233-245. 9. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis–2020 update. Endocr Pract. 2020;26(suppl 1):1-46. 10. Friedman J, Eslami M. Medical management of osteoporosis when bisphosphonates fail. Curr Transl Geriatr Exp Gerontol Rep. 2013;2:105-112. 11. Imel EA, Eckert G, Modi A, et al. Proportion of osteoporotic women remaining at risk for fracture despite adherence to oral bisphosphonates. Bone. 2016;83:267-275. 12. Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. US Department of Health and Human Services, Office of the Surgeon General; 2004. 13. Vescini F, Chiodini I, Falchetti A, et al. Management of osteoporosis in men: a narrative review. Int J Mol Sci. 2021;22(24):13640. 14. Lewis CE, Ewing SK, Taylor BC, et al. Predictors of non-spine fracture in elderly men: the MrOS study. J Bone Miner Res. 2007;22(2):211-219.